Vinflunine for the treatment of non-small cell lung cancer

References

• World Health Organization. Fact sheet N° 297; [updated Feb 2015; cited 2016 Jul 11]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
   Google Scholar
• American Cancer Society – Lung Cancer (Non-Small Cell). [cited 2016 May 16]. Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer
   Google Scholar
• European Medicines Agency: Vinflunine - Summary of product characteristics. [cited 2016 May 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000983/WC500039604.pdf
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines®) – Non-small cell lung cancer – version 4.2016. [cited 2016 May 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Saito M, Shiraishi K, Kunitoh H, et al. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016Mar;30. [Epub ahead of print]. 10.1111/cas.12941
   Web of Science ®Google Scholar
• Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol. 2016;5(1):1–20.
   PubMed Web of Science ®Google Scholar
• Genestreti G, Grossi F, Genova C, et al. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol. 2014;10(13):2081–2096.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Horwitz SB, Lobert S, et al. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol. 2008;35(Suppl 3):S6–S12.
   PubMed Web of Science ®Google Scholar
• Donehower RC, Rowinsky EK. Anticancer drugs derived from plants. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: J B Lippincott Company; 1993. p. 409–417.
   Google Scholar
• Moudi M, Go R, Yien CY, et al. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231–1235.
   PubMedGoogle Scholar
• Bennouna J, Delord JP, Campone M, et al. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14(6):1625–1632.
   PubMed Web of Science ®Google Scholar
• Vindya NG, Sharma N, Yadav M, et al. Tubulins - the target for anticancer therapy. Curr Top Med Chem. 2015;15(1):73–82.
   PubMed Web of Science ®Google Scholar
• Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60(18):5045–5051.
   PubMed Web of Science ®Google Scholar
• Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther. 2003;2(5):427–436.
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Etiévant C, Perrin D, et al. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer. 2002;86(1):143–150.
   PubMed Web of Science ®Google Scholar
• Ngan VK, Bellman K, Hill BT, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60(1):225–232.
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol. 2001;40(2):159–173.
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Barret JM, Etiévant C, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998;55(5):635–648.
   PubMed Web of Science ®Google Scholar
• Barret JM, Etiévant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol. 2000;45(6):471–476.
   PubMed Web of Science ®Google Scholar
• Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35(3):512–520.
   PubMed Web of Science ®Google Scholar
• Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001;84(2):290–295.
   PubMed Web of Science ®Google Scholar
• Pourroy B, Honoré S, Pasquier E, et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 2006;66(6):3256–3263.
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Poli M, Dossi R, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42(16):2821–2832.
   PubMed Web of Science ®Google Scholar
• Aparicio LM, Pulido EG, Gallego GA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs. 2012;23(1):1–11.
   PubMed Web of Science ®Google Scholar
• Rovini A, Gauthier G, Bergès R, et al. Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status. PLoS One. 2013;8(6):e65694.
   PubMed Web of Science ®Google Scholar
• Etievant C, Barret JM, Kruczynski A, et al. Vinflunine (20ʹ,20ʹ-difluoro-3ʹ,4ʹ-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs. 1998;16(1):3–17.
   PubMed Web of Science ®Google Scholar
• Etiévant C, Kruczynski A, Barret JM, et al. Markedly diminished drug resistance-inducing properties of vinflunine (20ʹ,20ʹ-difluoro-3ʹ,4ʹ-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol. 2001;48(1):62–70.
   PubMed Web of Science ®Google Scholar
• Estève MA, Carré M, Bourgarel-Rey V, et al. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther. 2006;5(11):2824–2833.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14(4):630–637.
   PubMed Web of Science ®Google Scholar
• Lobert S, Puozzo C. Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol. 2008;35(3 Suppl 3):S28–S33.
   PubMed Web of Science ®Google Scholar
• Zhao XP, Liu XQ, Wang YS, et al. Pharmacokinetics, tissue distribution and excretion of vinflunine. Eur J Drug Metab Pharmacokinet. 2006;31(2):59–64.
   PubMed Web of Science ®Google Scholar
• Delord JP, Ravaud A, Bennouna J, et al. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs. 2013;31(3):724–733.
   PubMed Web of Science ®Google Scholar
• Isambert N, Delord JP, Tourani JM, et al. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol. 2014;77(3):498–508.
   PubMed Web of Science ®Google Scholar
• Johnson P, Geldart T, Fumoleau P, et al. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24(3):223–231.
   PubMed Web of Science ®Google Scholar
• Calvo E, Vermorken JB, Hiret S, et al. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. Cancer Chemother Pharmacol. 2012;69(6):1467–1475.
   PubMed Web of Science ®Google Scholar
• Delord JP, Bennouna J, Mourey L, et al. Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials. Clin Pharmacokinet. 2012;51(6):357–364.
   PubMed Web of Science ®Google Scholar
• Delord JP, Tourani JM, Lefresne F, et al. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours. Cancer Chemother Pharmacol. 2013;71(3):647–656.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Breton JL, Tourani JM, et al. Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer. 2006;94(10):1383–1388.
   PubMed Web of Science ®Google Scholar
• Krzakowski M, Ramlau R, Jassem J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol. 2010;28(13):2167–2173.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Davies J, Walko C, et al. Phase I trial of vinflunine and pemetrexed in refractory solid tumors. Invest New Drugs. 2011;29(1):131–136.
   PubMed Web of Science ®Google Scholar
• Tournoux-Facon C, Senellart H, Lemarie E, et al. Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients. J Thorac Oncol. 2011;6(7):1247–1253.
   PubMed Web of Science ®Google Scholar
• Tournoux-Facon C, Robinet G, Pinel MC, et al. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer. Am J Clin Oncol. 2012;35(4):378–385.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Davies JM, Walko C, et al. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. Invest New Drugs. 2011;29(5):978–983.
   PubMed Web of Science ®Google Scholar
• Krzakowski M, Bennouna J, Dansin E, et al. Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol. 2014;73(2):231–236.
   PubMed Web of Science ®Google Scholar
• Souquet PJ, Krzakowski M, Ramlau R, et al. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11(2):105–113.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Lee CB, Hayes DN, et al. Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer. J Clin Oncol. 2008;26(15S):19100.
   Google Scholar
• Clinicaltrials.gov. NCT00519831; [cited 2016 Jun 12]. Available from https://clinicaltrials.gov/ct2/show/record/NCT00519831
   Google Scholar
• Barletta G, Genova C, Rijavec E, et al. Oral vinorelbine in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15(11):1585–1599.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–4461.
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Grossi F. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. Expert Rev Anticancer Ther. 2016;16(1):1–4.
   PubMed Web of Science ®Google Scholar
• Genestreti G1, Grossi F, Genova C, et al. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol. 2014;10(13):2081–2096.
   PubMed Web of Science ®Google Scholar
• Camerini A, Puccetti C, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359.
   PubMed Web of Science ®Google Scholar
• Bustamante Alvarez JG, Gonzáles-Cao M, Karachalious N, et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med. 2015;12(3):209–222.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. NCT01454102. [cited 2016 Jul 11]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01454102
   Google Scholar